Drug updated on 5/17/2024
Dosage Form | Injection (intravenous; 800 mg/50 mL [16 mg/mL]) |
Drug Class | Epidermal growth factor receptor (EGFR) antagonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Necitumumab (Portrazza) is indicated in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer.
- Two studies provided a detailed comparison of necitumumab's safety and effectiveness compared to other treatments.
- Studies show mixed results regarding progression-free survival (PFS), with one indicating longer PFS when using necitumumab combined with chemotherapy versus chemotherapy alone, while the other shows no statistically significant improvement.
- In terms of overall survival (OS), both studies suggest potential benefits from adding necitumumab to chemotherapy. This advantage appears more pronounced among patients exhibiting high epidermal growth factor receptor expression according to one study.
- Both studies agree that adding necitumumab leads to a higher incidence and severity of certain adverse events such as skin rash and hypomagnesemia.
- Subgroup considerations indicate that those with high EGFR expression or squamous histology may benefit more from this drug; however, it does not seem beneficial for patients having non-squamous NSCLC in terms of OS or objective response rate.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Portrazza (necitumumab) Prescribing Information. | 2015 | Lilly USA, LLC., Indianapolis, IN |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials. | 2021 | Annals of Palliative Medicine |
Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis. | 2020 | Journal of Oncology Pharmacy Practice |